Product Information
TOBRAMYCIN-DEXAMETH OPHTH SUSP is a generic product labeled by Padagis US LLC, priced at $4.1784 per ML under NDC 00574403110. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Feb 11, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1; 3 mg/mL; mg/mL
Manufacturer
Padagis US LLCNDC
00574403110
Classification
Generic
Dosage Form
SUSPENSION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
DEXAMETHASONE; TOBRAMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA212715FDA Approved
2/11/2022
TE Code
AB
On Market Since
3/17/2022
Pharmacological Classes
Price Statistics
The NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 68.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.1784 per ML |
|---|---|
| All-time high | $13.3557 (Oct 12, 2022) |
| All-time low | $2.8218 (Nov 20, 2024) |
| 52-week high | $4.9644 |
| 52-week low | $4.1561 |
| Median price | $4.8390 |
| Average price | $5.7628 |
| Largest weekly change | +67.2% (Aug 23, 2023) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tobramycin and dexamethasone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOBRAMYCIN-DEXAMETH OPHTH SUSP?
The current National Average Drug Acquisition Cost (NADAC) for TOBRAMYCIN-DEXAMETH OPHTH SUSP, manufactured by Padagis US LLC, is $4.1784 per ML (NDC 00574403110), effective Sep 30, 2026.
How has the price of TOBRAMYCIN-DEXAMETH OPHTH SUSP changed over time?
Over the history we have for it, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has declined 68.7%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for TOBRAMYCIN-DEXAMETH OPHTH SUSP?
Since Jun 1, 2022, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has ranged from a low of $2.8218 (Nov 20, 2024) to a high of $13.3557 (Oct 12, 2022), with a median of $4.8390 per ML.
Are there cheaper alternatives to TOBRAMYCIN-DEXAMETH OPHTH SUSP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOBRAMYCIN-DEXAMETH OPHTH SUSP, is $4.0121 per ML — about 4% below TOBRAMYCIN-DEXAMETH OPHTH SUSP.
Who manufactures TOBRAMYCIN-DEXAMETH OPHTH SUSP?
TOBRAMYCIN-DEXAMETH OPHTH SUSP (NDC 00574403110) is labeled by Padagis US LLC, and CMS classifies it as a generic product.